Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression-Reference-Cited by-同舟云学术

Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression

Published:2023-12-12 Issue: Volume: Page:
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Birdwell Christine E.,Fiskus Warren^ORCID,Kadia Tapan M.^ORCID,Mill Christopher P.^ORCID,Sasaki Koji^ORCID,Daver Naval^ORCID,DiNardo Courtney D.^ORCID,Pemmaraju Naveen^ORCID,Borthakur Gautam^ORCID,Davis John A.,Das Kaberi^ORCID,Sharma Sunil,Horrigan Stephen,Ruan Xinjia,Su Xiaoping,Khoury Joseph D.^ORCID,Kantarjian Hagop,Bhalla Kapil N.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-023-02108-3.pdf

Reference51 articles.

1. Birdwell C, Fiskus W, Kadia TM, DiNardo CD, Mill CP, Bhalla KN. EVI1 dysregulation: impact on biology and therapy of myeloid malignancies. Blood Cancer J. 2021;11:64.

2. Morishita K, Parker DS, Mucenski ML, Jenkins NA, Copeland NG, Ihle JN. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell. 1988;54:831–40.

3. Perkins AS, Fishel R, Jenkins NA, Copeland NG. Evi-1: a murine zinc finger proto-oncogene, encodes a sequence-specific DNA-binding protein. Mol Cell Biol. 1991;11:2665–74.

4. Delwel R, Funabiki T, Kreider BL, Morishita K, Ihle JN. Four of the seven zinc fingers of the Evi-1 myeloid-transforming gene are required for sequence-specific binding to GA(C/T)AAGA(T/C)AAGATAA. Mol Cell Biol. 1993;13:4291–300.

5. Zhang Y, Stehling-Sun S, Lezon-Geyda K, Juneja SC, Coillard L, Chatterjee G, et al. PR-domain-containing Mds1-Evi1 is critical for long-term hematopoietic stem cell function. Blood. 2011;118:3853–61.